Keywords: IL-2; bone marrow transplant; peripheral blood stem cell transplant Use of IL-2 therapy after autologous transplantation is currently being explored to reduce relapse rate. Low doses of the cytokine induce significant immunomodu-IL-2 immunotherapy is currently being explored after lation avoiding the severe side-effects associated with ABMT/PBSCT in an attempt to reduce cancer recurrence. high-dose IL-2 therapy. However, low-dose IL-2 is Although preliminary experience seems promising,
/day for 3 months by continuous intra-
In the BMT setting, IL-2 doses ranging from 5 to 20 venous infusion. Ten of these patients suffered infectious millions have resulted in fast immunomodulation with modepisodes, mainly bacteriemias that often necessitated erate-severe toxicity (severe hypotension, renal failure, delaying IL-2 therapy (median delivered dose: 32% of capillary leak syndrome) in about 30% of patients. 1,2,7 On planned). The next 13 patients were then assigned to the other hand, the Dana Farber group showed that intrareceive IL-2 (800 000-1 000 000 IU/m 2 /day for 3 months) venous continuous infusion of 200 000 IU/m 2 /day of IL-2 subcutaneously (group B). For group B patients, median increased NK populations with much less clinical toxicity. 6 dose intensity was 84% (P = 0.01 when compared with With continuous intravenous administration of IL-2, we 8 group A patients). Only one severe infectious episode and others, 9, 10 have observed a high rate of infectious epiwas observed in these patients. Clinical toxicity in group sodes, probably related to the prolonged use of central B patients consisted mainly of s.c. nodules. Immunomovenous lines. 11 Consequently, we started to treat our dulation, measured as an increase in the absolute numpatients with low-dose IL-2 by the subcutaneous route. ber of CD56 + cells and CD56 +bright cells, was higher in Here, we report our experience with respect to immunomopatients who received the cytokine by the subcutaneous dulation and toxicity with both routes of administration.
route (median peak increase of CD56
+ cells: 160 and Our results support that, at the doses used in the study and 220% for group A and B patients respectively; median after autologous hematopoietic progenitor transplantation, peak increase of CD56 +bright cells: 210% and 310% for it is possible to induce significant immunomodulation group A and B respectively, P Ͻ 0.05 between groups with the subcutaneous schedule, with reduced incidence of A and B). No statistically significant increment of T lyminfectious episodes when compared to IL-2 therapy phocytes was observed in any group. No hematologic intravenously. toxicity was observed apart from eosinophilia, which was very marked in group B (P Ͻ 0.01). Our results show that low-dose s.c. IL-2 therapy is associated with low clinical and hematologic toxicity after autologous Patients and methods transplantation. The immunomodulation achieved is no less than that achieved with the i.v. approach.
Patients Treatment with IL-2 began once a stable hematologic in children) once a day for 3 months (group A). Patients received acetaminophen if malaise or chills developed. ILengraftment had occurred (granulocyte count Ͼ1500/mm 3 ; platelet count Ͼ50 000/mm 3 for at least 2 weeks), no renal 2 was temporarily discontinued and then restarted at half the initial dose when infection or severe side-effects or liver failure (creatinine Ͻ1.3 mg/dl, bilirubin Ͻ3 mg/dl), no active infection and no prior therapy with growth factors occurred. When symptoms abated, the dose was escalated back over 2-3 weeks. for at least 7 days.
Twenty-six consecutive patients met these criteria and have received low-dose IL-2 therapy after ABMT (n = 10),
Follow-up studies PBSCT (n = 12) or ABMT + PBSCT (n = 4) since September 1992 (Table 1) . Nine patients were in first complete Clinical monitoring complete blood count, serum chemistry remission while the other 17 had more advanced disease profile, prothrombin time, activated partial thromboplastin just prior to transplantation (12 in second complete time (APTT), fibrinogen and lymphocyte subpopulations remission and five with active disease). Reasons for perwere performed on each visit. Visits were scheduled on forming transplantation in first complete remission included days 0, 15, 30, 60 and 90 after starting IL-2. NHL in the high-risk international index (n = 4), PhiladelFor immunological studies, peripheral blood monophia-positive ALL (n = 1), ALL in a 1-year-old patient (n nuclear cells were isolated from heparinized blood by Fic-= 1) and locally advanced breast neoplasm (n = 3).
oll-Hypaque density centrifugation. These cells were thereConditioning regimens included cyclophosphamide plus after incubated with fluorochrome-conjugated MoAbs for busulphan (n = 6) or total body irradiation (n = 2) for leuke-30 min at 4°C. After being washed twice, the stained cells mia; cyclophosphamide, BCNU and VP-16 for lymphoma were analyzed using a FACS Star Plus (Becton Dickinson, (n = 7); melphalan ± total body irradiation (n = 2) for mulMountain View, CA, USA). Lymphocyte gates were set tiple myeloma and carboplatin, thiotepa and cyclophosbased on forward and horizontal light scatter. tral nervous system involvement.
Disease status before transplant
In group A, seven patients did not complete the schedFirst complete remission 7 6 uled therapy because of infections that necessitated central Over the whole group, the median dose delivered was 133 300 IU/m 2 /day (32% of scheduled).
Median intensity dose 133 (6-383) 986 (815-1175) (% of scheduled) 32 (1.5-100) 84 (6.2-100)
In group B, two patients were withdrawn from the study because of severe headache (n = 1) and relapse while on IL-2 therapy (n = 1). These results were statistically sigantigen, CD56, also increased in all patients receiving IL-2 and was more marked in group B patients (peak percent nificant when compared with group A patients (53.8% and 15.3% of patients did not complete the study in group A increase in the absolute number of CD56 +bright cells: 310 and 210% for groups B and A respectively, P Ͻ 0.05). This and B respectively; P Ͻ 0.05). In this group, the median dose delivered was 812 700 IU/m 2 /day (84% of scheduled; maximum increment was observed 3 months after starting IL-2 in both groups. P = 0.01 with respect to group A patients). Only one patient suffered a 10-day delay in ending IL-2 therapy because of Dual-color immunofluorescence studies provided further information on the effects of IL-2 on NK cells in vivo. Figure 1 . In contrast to the proliferation of NK cells induced by IL-2, no statistically significant changes were observed in Briefly, the fraction of lymphocytes expressing the NK cellassociated antigen CD56 increased steadily over time, riscirculating T lymphocytes (Figure 1b ). ing to a median of 1. 6 Figure 1a) . and/or bone pain. Another patient, with previous central Density of membrane expression of the NK cell surface nervous system involvement, developed moderate headache. Infections were the most common complication observed during IL-2 treatment, and 17 infectious episodes were observed in 10 patients: 14 septicemias (seven due to gram-negative micro-organisms, seven to gram-positive and two mixed) and one candidemia. The first infectious episode was observed at a median of 22 days (range: 2-55) after initiating IL-2. Since patients early post-transplant may be more susceptible to infections, the incidence of infections was also analyzed for patients who started IL-2 therapy after day +60: four of six patients in group A developed at least one infectious episode while no infection was observed in patients who started IL-2 after day +60 in group B. Three patients in group B developed low-grade fever and two moderate-severe headache. Another patient suffered from Candida parapsilosis fungemia on day +34 of IL-2 therapy (incidence of infection: 76.9 and 7.6% for groups A and B respectively; P Ͻ 0.01). The most commonly reported side-effect was a local reaction at the site of infection manifested by erythema 1-3 cm in diameter with painful induration. Histological examination of nodular lesions in three patients was performed and showed a perivascular eosinophilic infiltrate with a modest mononuclear infiltrate positive for CD56 mainly. 12 The infiltrate was also evident, although to a lesser degree, outside the sites where IL-2 was given in the two patients in whom a biopsy of 'healthy skin (without nodular lesions)' was performed. numbers remained stable during IL-2 therapy in s.c. patients and decreased slightly in patients who received the cytokine intravenously (Figure 2b) .
Absolute figures of granulocytes, lymphocytes and monwere 5.5 pg/ml (range: 3.4-36) and 7.7 pg/ml (range: 0-159) with no differences between s.c. and i.v. patients. ocytes during IL-2 treatment are shown in Figure 3a . Briefly, group B patients had insignificantly lower numbers Group A patients maintained IL-2 concentrations of 1-2 IU/ml during the study period. IL-2 plasma concenof neutrophils, lymphocytes, monocytes and platelets, due probably to the inclusion of four heavily pre-treated acute trations in group B patients were below the limit of detection of the assay (0.56 IU/ml) just before the next IL-2 leukemia patients in this group. No clinically significant changes in these populations were observed during therapy administration in eight of 13 (61.5%) patients. In the other five patients, median (range) IL-2 levels while on IL-2 therwithin each group except for an increase in lymphocytes 3 months after starting IL-2 in group B. Eosinophil numbers apy were 0.75 IU/ml (0.61-0.82). Pharmacokinetic studies were performed up to 6 h after s.c. injection in three increased in both groups although the increment was more marked in group B patients (P Ͻ 0.01 from 2 months after patients. Peak levels were between 9 and 10 IU/ml 2-4 h after IL-2 dose. starting IL-2). Analysis of hematological toxicity remained similar if the four heavily treated acute leukemia patients were excluded from the analysis: no hematological toxicity except for a more marked increase in eosinophils in group Discussion B patients was observed.
Basic coagulation parameters and clinical biochemistry Low-dose IL-2 therapy after ABMT/PBSCT has been shown to produce less extrahemopoietic toxicity than when did not change during therapy with IL-2 in any group (data not shown).
it is used at higher doses. 6, 13 However, continuous intravenous administration of the cytokine is associated with an incidence of infectious complications of approximately IL-2 and TNF levels 40% in the BMT and non-BMT setting. 9, 14 Although some authors have observed a defect in neutrophil function asso-TNF levels increased slightly with IL-2 therapy (P Ͻ 0.05). Median values just prior to starting IL-2 and 1 month later ciated with IL-2 therapy, 15,16 a reduction of humoral responses, 17 in vitro preferential stimulation of the growth life-threatening, caused severe morbidity. The Roswell Park group has also observed these local reactions in AIDS of virulent strains of E. coli 18 and prolonged administration of IL-2 through central venous lines may be responsible for patients, even at doses of 400 000 IU/m 2 /day, and the severity of these local responses did not correlate with either the high incidence of septicemias. Moreover, maintenance of indwelling catheters is cumbersome and often associated dose (up to 1 400 000 IU/m 2 /day) or the number of days on the study. Biopsy of these lesions in three patients showed with thrombosis.
Principally because of the high incidence of infections a perivascular eosinophil infiltrate and a CD56 + cell infiltrate of the skin, not observed in control autologous transobserved by us with the low-dose IL-2 intravenous schedule in the first 13 patients (10/13; 76.8%), 8 we explored the plant patients, suggesting immune activation of NK cells at injection sites. 12 subcutaneous approach in the next 13 transplant patients. Due to pharmacokinetic differences, 19,20 we escalated IL-2 Finally the optimal tolerated dose of subcutaneous IL-2 remains to be determined. The dose used by us was well doses during the first 2 weeks of therapy to up to 2.5 times the intravenous dose to achieve low but relatively extended tolerated in these transplant and acute leukemia patients.
26
In AIDS patients, doses of up to 1 200 000 IU/m 2 /day are plasma concentrations of IL-2.
As expected, IL-2 plasma concentrations were different safe, while doses of 1 400 000 IU/m 2 /day are associated with grade III toxicity including fatigue and fever. 21 In the in both groups. Group A patients (i.v. schedule) maintained a constant plasma concentration of 1-2 IU/ml. Patients in BMT setting 400 000 IU/m 2 /day, just after the transplant, did not increase transplant-related toxicity. 5 In contrast, group B (s.c. schedule) had peak levels around 10 IU/ml 2 to 4 h after IL-2 administration, with concentrations below a preliminary report from the Dana Farber group showed severe toxicity, mainly high fever and constitutional 1 IU/ml just before the next dose: in 61.5% of group B patients IL-2 levels were below the detection limit of the symptoms, with IL-2 doses of 600 000 IU/m 2 /day after autologous bone marrow/peripheral blood stem cell trans-ELISA assay used (0.56 IU/ml). These results are consistent with those published by Bernstein et al in AIDS plantation. 27 In summary, our results show that immune modulation patients.
21
Immunomodulation (measured as the increment of absolwith low doses of IL-2 is possible after autologous marrow and peripheral blood stem cell transplantation. The subcuute numbers of CD56 + cells) was not inferior in group B patients and the number of CD56 + cells was statistically taneous route of administration produces similar immunomodulation to that seen with intravenous administration, significantly higher from day +60 in patients receiving IL-2 by the subcutaneous route. CD56 +bright cells also increased and is associated with a reduced incidence of infections, which may be related to the use of central venous lines. in both groups and this increment also reached statistical significance for group B patients. Although we did not mea-
The main toxicities of IL-2 administered by this route are eosinophilia and subcutaneous nodules. Controlled trials sure cytotoxic function, this increase in the NK population has been associated with an increment in cytotoxicity. 22 are necessary to evaluate the use of IL-2 administered with this schedule. T lymphocyte populations did not change. This is consistent with previous experience 6 showing that, at the IL-2 levels achieved with these schedules, immunomodulation is only achieved in NK cells. These results are in agreement Acknowledgements with the expression of the high-affinity IL-2 receptor in some NK cells and the consequent ability to bind picomolar This work was supported in part with two FIS grants front the concentrations of IL-2 that were present in the serum of Clinical tolerance of IL-2 therapy was similar with both schedules. However, the incidence of bacteriemias/ fungemias was markedly reduced in group B patients (76.9 vs References 7.6%; P Ͻ 0.01), suggesting a role of indwelling catheters in the genesis of these infections as previously reported by A reduction in platelet numbers in group A patients was
